About Our Research Training
Trainees interested in pursuing a career in research investigation have a wide variety of opportunities ranging from HIV clinical research including behavioral and epidemiologic studies to bench work focusing on vaccine development, host-responses, and innate immunity. To make the transition to the research years, the fellowship leaders will meet several times during first year of fellowship to assist the fellow in identifying a specific area of research and potential research mentors. Once identified, fellows will work with this designated mentor throughout the remainder of their training. This mentor will supervise a fellow's development into an independent investigator which includes the development and implementation of research projects, publications, and grant submissions that will be used to obtain funding for project support and salary support in the non-ACGME years. Listed below are some of the research mentors within the Division of Infectious Diseases at BIDMC and their research interests.
Our Research Mentors
Carolyn Alonso, MD
Dr. Carolyn Alonso serves as the Director of the Transplant and Immunocompromised Host Program at Beth Israel Deaconess Medical Center. Her research focuses on the epidemiology and outcomes of C. difficile infection among immunosuppressed patients. Dr. Alonso has several open clinical trials in C. difficile research as well as an investigator-initiated grant to study C. difficile immune response within transplant and immunocompromised patients. Additional areas of active research investigation include clinical trials evaluating invasive fungal infections as well as a trial investigating patients treated with systemic mold-active triazole medications. Learn more about Dr. Alonso.
Dan Barouch, MD, PhD, FIDSA
Dr. Barouch is the Director of the Center for Virology and Vaccine Research at BIDMC. His research focuses on studying the immunology and virology of HIV-1 infection and developing novel vaccine strategies. Dr. Barouch's team has demonstrated that humoral and cellular immune responses elicited by adenovirus and poxvirus vectors can partially protect against acquisition of infection and can control viral replication following pathogenic virus challenges in rhesus monkeys. They have also developed a series of alternative serotype and chimeric adenovirus vector-based vaccines that are designed to circumvent the high titers of neutralizing antibodies to the common adenovirus serotype 5 (Ad5) vector in the developing world. They have constructed a variety of novel vaccine vectors, explored their immunogenicity and protective efficacy in preclinical studies, and advanced optimal vaccine candidates into clinical trials. Four phase 1 clinical trials with these novel HIV-1 vaccine vectors are currently in progress in the United States and sub-Saharan Africa. Dr. Barouch's group is a key part of the Bill and Melinda Gates Foundation Collaborative for AIDS Vaccine Discovery (CAVD), the NIH Center for HIV/AIDS Vaccine Immunology (CHAVI), and the Ragon Institute of MGH, MIT and Harvard. Learn more about Dr. Barouch.
Michelle Chan, MD
Dr. Chan received her MD from Case Western Reserve University and completed internal medicine residency at Ohio State University Wexner Medical Center. She then went on to complete infectious disease fellowship at Beth Israel Deaconess Medical Center. Her current research focuses on investigating the use of antibiotics at the end of life in the hematology/oncology population. Her interests include general infectious diseases, antibiotic stewardship, and infection control.
Douglas Krakower, MD
Dr. Douglas Krakower is a member of the faculty in the Division of Infectious Diseases at the BIDMC, Research Scientist at The Fenway Institute, and Assistant Professor in Medicine and Population Medicine at Harvard Medical School. His research focuses on ways to optimize HIV prevention in health care settings with a focus on implementing HIV pre-exposure prophylaxis (PrEP).
Dr. Krakower and colleagues are using predictive analytics to identify candidates for PrEP using electronic health records data. These NIH-funded projects are focused on several important clinical settings and populations in the US, including: OCHIN, a national network of safety-net community health centers (R34MH122291); four public health clinics in Jefferson County, Alabama (Supplement to P30 AI060354); and women at risk for HIV infection in Duval County, Florida (Supplement to R01MD013565). He is also Site Principal Investigator at the Fenway Institute for HIV Prevention Trials Network 083-01, a safety, tolerability and acceptability study of long-acting cabotegravir (CAB LA) for the prevention of HIV among adolescent males in the US (https://www.hptn.org/research/studies/083-01).
As of March 2020, he is co-leading a multidisciplinary COVID-19 clinical observational data repository at BIDMC. This repository will support observational studies at BIDMC and across a collaborative network of academic medical centers in the greater Boston region. He is a member of the Executive Committee of the Harvard University Center for AIDS Research (HU CFAR) and the BIDMC Site Director for the HU CFAR's Clinical Core. His clinical practice encompasses general infectious diseases and HIV treatment and prevention. Learn more about Dr. Krakower.
Jeffrey Larnard, MD
Dr. Larnard received his MD from the University of Massachusetts Chan Medical School and completed his Internal Medicine training at New York Presbyterian-Columbia prior to coming to BIDMC for Infectious Disease fellowship and staying on as faculty. He is interested in all things medical education and completed the Clinician-Educator Track for Fellows during his Infectious Disease training at BIDMC. Currently, his research focus is investigating antimicrobial prescribing at the end of life to inform future educational and/or stewardship initiatives in this population. He is also starting as Medical Director of Outpatient Parenteral Antibiotic Therapy (OPAT) and is looking forward to improving the care of ID patients as they are transitioned across care settings.
Mary LaSalvia, MD
Dr. LaSalvia joined the faculty in 2013 after serving as a resident, chief resident, and infectious diseases fellow at Beth Israel Deaconess Medical Center (BIDMC). She currently serves as the Interim Chief of the Division of Infectious Diseases while also continuing to be the Clinical Director of the Division of Infectious Diseases and Medical Director of Ambulatory Clinical Operations in the Department of Medicine as well as Medical Director of Ambulatory Quality in the Silverman Institute of Health Care Quality.
Clinically, her focus is on the care of patients with endovascular infection, bone & joint infection, and diabetic foot infection, as well as the management of outpatient intravenous antibiotic therapy. My quality improvement and research endeavors within infectious diseases are focused on the care of patients in our ambulatory clinics as well as the clinical care of patients requiring infectious diseases consultation including the standardization of management of S. aureus bacteremia, diabetic foot osteomyelitis, and the safety of outpatient parenteral antibiotic therapy.
In her role as Medical Director of Ambulatory Quality at BIDMC, her current focus is on the standardization of closed loop communication of test results, imaging, and referrals as well as the development of an ambulatory safety net program with a focus on cancer screening. Learn more about Dr. LaSalvia.
Matthew Lee, MD
After obtaining his medical doctorate from Georgetown University and completing Internal Medicine residency at New York University, Dr. Lee joined the Beth Israel Deaconess Medical Center Infectious Diseases Fellowship program. He completed two years of clinical fellowship followed by an additional third-year of advanced fellowship focusing on Antimicrobial Stewardship. His interests include antimicrobial stewardship (research and program development) and medical education. He has merged these two interests as a member of the Infectious Diseases Society of America Antimicrobial Stewardship Curriculum Workgroup. Learn more about Dr. Lee.
Kenneth Mayer, MD, FIDSA
Dr. Mayer has been conducting bio-behavioral studies of HIV prevention in high-risk populations in the US at Fenway Health, and in several international studies overseas, particularly India. He has led studies of HIV chemoprophylaxis (PEP, PrEP, and topical microbicides), vaccines, as well as social and structural interventions. He is the New England site Principal Investigator for the NIH's HIV Prevention Trials Network (HPTN) and Microbicides Trials Network (MTN) consortia; and co-PI of the Harvard HIV Vaccine Trials Unit. He was one of the national chairs of HPTN 061, a study focused on developing HIV prevention interventions for Black men who have sex with men, and is Protocol Co-Chair of HPTN 069, which is evaluating Maraviroc for use as PrEP. He is also funded by NIMH to work with behavioral scientists to develop adherence interventions for PrEP users.
Dr. Mayer is also involved with several natural history studies of HIV, including the CFAR Network of Clinical Integrated Systems (CNICS), which follows more than 30,000 HIV-infected patients in care at 8 US centers. He is also leading an effort to train other community health centers to use their electronic health records to conduct clinical research. His recent papers have appeared in the Annals of Internal Medicine, Lancet, New England Journal of Medicine, AIDS, Journal of AIDS, Clinical Infectious Diseases, and other journals. He continues to work with several centers in India, and is part of the Executive Committee of the HPTN, working on developing combination HIV prevention interventions. Learn more about Dr. Mayer.
Ruvandhi Nathavitharana, MB, BS, MPH
Dr. Ruvandhi Nathavitharana is a TB researcher and attending physician in Infectious Diseases at Beth Israel Deaconess Medical Center and an Assistant Professor at Harvard Medical School. Dr. Nathavitharana's research interests center around the use of implementation science to evaluate TB diagnostic algorithms and interventions to decrease TB transmission in high TB incidence countries with a focus on Peru and South Africa, funded by an NIH K23 Career Development Award and ASTMH Burroughs Wellcome Fellowship. Dr. Nathavitharana has served as a technical expert analyzing data to inform WHO guideline development group panel recommendations on the use of line probe assays and the urine lipoarabinomannan test for the diagnosis of TB. Dr. Nathavitharana is also the Vice Chair of TB Proof, an advocacy organization based in South Africa that seeks to destigmatize TB and mobilize national and global resources to end TB.
Dr. Nathavitharana's clinical efforts are focused on the longitudinal, multidisciplinary care of patients with TB and non-tuberculous mycobacteria (NTMs). In addition to providing dedicated teaching on the management of mycobacterial infections to BIDMC fellows and residents, she serves as a local expert for a quarterly webinar entitled "Issues in the Clinical Management of TB" that is co-hosted by experts at Johns Hopkins and UCLA. Learn more about Dr. Nathavitharana.
Christopher Rowley, MD, MPH
Dr. Rowley is an Assistant Professor of Medicine at Harvard Medical School and a past member of the Essex Laboratory at the Harvard School of Public Health. His primary laboratory interests were related to HIV drug resistance in southern Africa and he was the principal investigator of an NIH-funded study to monitor for transmitted HIV drug resistance in Botswana and has worked to develop techniques allowing for low cost alternatives for resistance testing. Since leaving the laboratory, he has served as the Associate Program Director for the ID Fellowship and has been engaged in research within the Infectious Diseases Division related to the infectious complications of opioid use disorder. He currently serves on the hospital-wide Opioid Care Committee and as the Director of Opioid Use Disorder Education for the Department of Medicine at the BIDMC. Learn more about Dr. Rowley.
Roger Shapiro, MD, MPH
Dr. Shapiro is an Associate Professor in Medicine at Harvard Medical School and the Harvard TH Chan School of Public Health. His research involves improving birth outcomes and childhood survival among HIV-exposed infants in the developing world. He has led several studies to evaluate new strategies to prevent mother-to-child transmission (PMTCT), including the use of maternal antiretroviral therapy (ART) in breastfeeding. He is currently the principal investigator on studies in Botswana that evaluate the relationship between antiretroviral therapy and adverse birth outcomes, risk factors for childhood mortality, the potential benefit of very early antiretroviral treatment for HIV-infected infants in the Early Infant Treatment Study, and use of broadly neutralizing monoclonal antibodies (bNAbs) as a treatment strategy for HIV-infected children. He is the co-investigator on studies to evaluate neurodevelopmental outcomes in children exposed to antiretrovirals and community-wide combination prevention strategies to reduce HIV incidence. He is also an active research and clinical mentor in Botswana and Boston, and mentor within a teaching and training program that he initiated for rotating Harvard-based clinicians at one of the district hospitals in Botswana. The results of his research in Botswana have been used to direct health policy in Botswana and internationally, and through this work, he has become a scientific advisor to the World Health Organization for the development of guidelines for PMTCT, pediatric antiretroviral treatment, and infant feeding. Learn more about Dr. Shapiro.
Wendy Stead, MD
Dr. Stead received her MD from the University of Massachusetts and completed her Internal Medicine Residency and ID Fellowship at Beth Israel Deaconess Medical Center, joining the BIDMC faculty with a joint appointment in the Divisions of Infectious Diseases and General Medicine and Primary Care in 2003. She completed a Rabkin Fellowship in Medical Education in 2010 and dedicates herself to patient care, medical education, and curriculum development work at the residency and fellowship levels, winning many awards for teaching, mentorship, and humanistic care. She currently serves as Chief of the Hermann Blumgart Firm for BIDMC's Internal Medicine Residency Program and as Program Director of the BIDMC Infectious Diseases Fellowship. Her active research interests include examining the effects of interdisciplinary education strategies on collaboration between specialty services, communication skills in patients with opioid use disorders, trainee wellness, and gender bias in academic medicine. She also loves narrative medicine and writing stories about her inspiring patients and has been fortunate to have several essays published in JAMA's Piece of my Mind. Learn more about Dr. Stead.
Kathryn Stephenson, MD, MPH
Dr. Stephenson is a physician-scientist who specializes in infectious diseases and HIV immunology, and the goal of her research is to develop novel biomedical interventions to prevent and treat HIV and emerging infectious diseases. In particular, she is interested in the design and evaluation of HIV vaccines and monoclonal antibodies that can be effective in the face of tremendous HIV sequence diversity, as well as in the development of Zika and COVID-19 vaccines. As an immunologist, her expertise is in the extensive epitope mapping of cellular and humoral immune responses. As a clinical investigator, her expertise is in the translation of novel vaccines and monoclonal antibodies into First-in-Human, Phase 1 clinical trials, and she is the Director of the Center for Virology and Vaccine Research Clinical Trials Unit. She is also Associate Editor of Clinical Immunology. Learn more about Dr. Stephenson.
Dana Pepe, MD
Dr. Pepe is a Medical Director and Associate Hospital Epidemiologist in the Division of Infection Control/Hospital Epidemiology, Infectious Diseases attending in the Division of Infectious Diseases, and Instructor in Medicine at Harvard Medical School. She completed her undergraduate studies in Biology at New York University, and went on to pursue a Masters in Public Health in Environmental Health Sciences at Columbia University Mailman School of Public Health. Dr. Pepe then attended medical school at New York Medical College and completed her Internal Medicine residency at MedStar Georgetown University Hospital. She completed her Infectious Diseases fellowship at Yale School of Medicine/Yale New Haven Health, and spent an additional year as an inaugural Leadership in Epidemiology, Antimicrobial Stewardship and Public Health (LEAP) Fellow, sponsored by IDSA, SHEA, PIDS and funded by CDC. Dr. Pepe's interests include healthcare-associated infections, specifically catheter-associated urinary tract infections (CAUTIs), sustainability in healthcare, emerging infectious diseases and environmental impacts on health. Learn more about Dr. Pepe.
Nira Pollock, MD, PhD
Dr. Pollock is the Associate Medical Director of the Infectious Diseases Diagnostic Laboratory at Boston Children's Hospital and a faculty member of the Division of Infectious Diseases at Beth Israel Deaconess Medical Center (BIDMC) in Boston. She is an Associate Professor of Pathology at Harvard Medical School, with a joint appointment in Medicine. She completed her MD/PhD at the University of California, San Francisco; her medical residency at Brigham and Women's Hospital in Boston; and her infectious diseases/clinical microbiology fellowships at BIDMC.
Dr. Pollock has an active research program focused on the development and evaluation of novel diagnostics for infectious diseases and related applications. Her diagnostics research has spanned a range of diseases including C. difficile infection, active and latent tuberculosis, influenza, Lyme disease, sexually-transmitted infections, and Ebola virus disease (EVD), and has involved many different technologies, ranging from simple paper-based lateral flow and microfluidic platforms to novel automated platforms for protein and nucleic acid detection. Learn more about Dr. Pollock.
Conor Stack, MD
Dr. Stack's current interests are in studying and developing antimicrobial stewardship (AS) and quality improvement interventions designed to optimize antimicrobial prescribing. His recent research includes a study of hepatobiliary surgical site infections at BIDMC designed to determine if the antibiotic surgical prophylaxis guidelines in place at our institution are optimal. He has also led an investigation of risk factors for fluconazole non-susceptible Candida in order to validate an empiric treatment algorithm for candidemia at the institution. He is currently investigating the use of rapid multiplex viral PCR testing and its impact on antimicrobial use in immunocompromised patients. In addition to helping to develop the AS curriculum for fellows at BIDMC, Dr. Stack is also a member of a working group at the Infectious Diseases Society of America tasked with developing a national AS curriculum for infectious diseases fellows. His clinical interests are broad and include general and immunocompromised infectious diseases as well as HIV. Learn more about Dr. Stack
Peter Weller, MD, FIDSA
Dr. Weller has many active areas of basic laboratory research centered around understanding basic mechanisms of leukocyte functioning in forms of inflammation. The two principal areas of investigation are:
- The immunobiology of eosinophilic leukocytes
- The intracellular regulation and compartmentalization of inducible mediators of inflammation in neutrophils and other leukocytes.
Studies of human eosinophils are aimed at defining mechanisms whereby eosinophils may collaboratively interact with other cellular elements of the immune system. These studies include investigations of the mechanisms whereby eosinophils may function as antigen-presenting cells in governing T-lymphocyte dependent immune responses, and include investigations of the in vivo migration and function of eosinophils and of the regulated expression of cell surface proteins involved in collaborative interactions between eosinophils and other cell types.
Additional studies are focused on defining the molecular mechanisms governing the synthesis, granule storage and release mechanisms of eosinophil derived cytokines. The roles of eosinophils in wound healing and fibrosis and the activities of chemokines and cytokines released by eosinophils that contribute to tissue remodeling are being studied. The second area of research involves the molecular and cellular biologic bases of inducible responses of leukocytes participating in host defense and other forms of inflammation. These are centered on a unique intracellular compartment, termed the lipid body, whose formation is rapidly inducible in leukocytes. The intracellular signaling mechanisms responsible for lipid body induction and especially the roles of lipid bodies as distinct sites of cytokine and eicosanoid mediator formation are being studied.
In addition to investigating previously undefined pathways of leukocyte responses to inflammation, these studies also offer the potential to identify novel anti-inflammatory therapeutic targets. Our research indicates that lipid bodies in leukocytes have roles as sites of regulated formation of eicosanoids and as distinct extranuclear sites of translation. The biology of these structures is intimately related to the roles of leukocytes in acute inflammation. Learn more about Dr. Weller.
Robin E. Wigmore, MD
Dr. Wigmore received her MD from The George Washington University. She completed her internal medicine residency at Tufts Medical Center. She had the honor of spending an additional year at Tufts Medical Center as Chief Resident. She then began her infectious disease fellowship at Beth Israel Deaconess Medical Center Disease in 2008 and joined as staff in 2010. Her focus is on both infectious diseases as well as general internal medicine with a joint appointment in primary care. Her interests include primary care of people living with HIV, hepatitis, tick borne illnesses, recurrent UTI’s, management of outpatient antibiotic therapy, and general infectious diseases.
In addition to weekly ambulatory clinics, she attends on the general, immunocompromised, and attending only inpatient services and enjoys her role in fellow education. Her interest in medical education also reaches to residents and students as she serves as the residency and medical student elective coordinator and clerkship director. She also coordinates the weekly HIV and primary care conference, which is funded through a New England AIDS Education Training Center (NEAETC) grant and provides a multidisciplinary arena to discuss challenges in HIV care as well as invited outside speakers from multiple divisions and regional medical centers. Learn more about Dr. Wigmore.
Sharon Wright, MD, MPH, FIDSA, FSHEA
Dr. Sharon Wright is the Senior Medical Director of the Division of Infection Control/Hospital Epidemiology and Hospital Epidemiologist in the Silverman Institute for Health Care Quality and Safety at Beth Israel Deaconess Medical Center (BIDMC). She has served in this position since 2001. She is an Associate Professor of Medicine at Harvard Medical School and is on the faculty of the Division of Infectious Diseases at Beth Israel Deaconess Medical Center. Dr. Wright received her medical degree from the Columbia Vagelos College of Physicians and Surgeons and her master’s degree in public health from the Harvard T. H. Chan School of Public Health. She completed her internal medicine residency at Columbia Presbyterian Medical Center and her infectious diseases fellowship in the Harvard Combined (Longwood) Training Program. She completed a second fellowship in Health Services Research at Boston Children's Hospital.
At BIDMC, Dr. Wright's work has focused on prevention of healthcare-associated infections, in particular novel approaches to reduction of central-line associated bloodstream infections, surgical site infections and outbreak management. In 2016, she led an institution-wide de-implementation of Contact Precautions for MRSA and VRE, including development of multimedia educational materials for staff. Dr. Wright co-chairs the Influenza Vaccination Steering Committee and led the efforts around H1N1 prevention and the institution of mandatory influenza vaccination for direct care health care personnel. Most recently, she has focused on developing a pipeline for training infection control practitioners at BIDMC and also partners with the School of Nursing and the Health Sciences Program at Northeastern University to encourage students to enter the field.
Nationally, Dr. Wright is currently serving as Vice President on the Board of Trustees of the Society of Healthcare Epidemiology of America (SHEA). Her research interests include the epidemiology and transmission of community-associated MRSA, prevention of healthcare-associated infections, and training of both infectious diseases fellows and infection control practitioners in infection prevention. Over the last 19 years, Dr. Wright has mentored 20 fellows in infection control and research and all have gone on to careers in healthcare epidemiology and health care quality. She created a funded infection control fellow track with a set curriculum for senior infectious diseases fellows planning a career in healthcare epidemiology in order to provide hands-on experience in surveillance, quality improvement, and administration. Learn more about Healthcare Epidemiology Research Training.
Rebecca Zash, MD
Dr. Zash is an Assistant Professor at Harvard Medical School, part of the Shapiro group at the Harvard TH Chan School of Public Health and a Research Associate with the Botswana Harvard AIDS Institute Partnership. The focus of her research is HIV in pregnancy and developing methodology to evaluate medication safety in pregnancy in low resource settings. Since 2014 she has helped to lead a large birth surveillance study in Botswana ('Tsepamo') to evaluate the safety of antiretroviral medication in pregnancy. Tsepamo collects information on a broad range of maternal and infant outcomes, from stillbirth and preterm delivery to maternal hypertension and anemia. High-profile findings from this study, about the association of dolutegravir and neural tube defects, have informed HIV treatment guidelines worldwide. Dr. Zash also leads a study to understand the mechanism of adverse birth outcomes among women with HIV on ART, with a focus on gestational hypertension, weight gain and endothelial dysfunction. In addition, Dr. Zash is a member of the DHHS Perinatal HIV Guidelines Committee and the Associate Director for Global Health Programs for the Internal Medicine Residency. Learn more about Dr. Zash.
Mentorship Outside of BIDMC
BIDMC fellows have the opportunity to work with primary mentors outside the BIDMC at one of the Harvard affiliated hospitals. Our fellows have a track record of working with mentors from Massachusetts General Hospital, Children's Hospital Boston, Brigham and Women's Hospital and The Ragon Institute. Fellows interested in working with mentors outside of BIDMC will continue to meet regularly with a BIDMC advisor throughout their fellowship training.
The Infectious Diseases Fellowship Training Program at Beth Israel Deaconess Medical Center, Harvard Medical School is a fully ACGME-accredited program that offers comprehensive Infectious Diseases clinical training and education and many different research opportunities. Trainees joining our fellowship program will participate in the primary and consultative care for a diverse population of patients at BIDMC.
Scholarship Oversight Committee
A scholarship oversight committee (SOC) meets with each first year fellow just prior to the end of the first year of fellowship and again halfway during the second year of fellowship. The primary purpose of the SOC is to provide additional mentorship for the fellow as they start their research year and it consists of several ID faculty members with different research backgrounds. The SOC serves as a sounding board for the fellow and mentor to address any issues that may arise while working on the research project and creates a formal process where the research can be presented to a group that is not intimately familiar with the research to receive their constructive feedback. The SOC will offer suggestions about what seems feasible during this time period, raise different approaches to address residual questions which may not have been considered, and review and monitor the timeline of the research to ensure that progress is being made so the work can be completed. Individual members of the SOC often serve as informal mentors outside of the formal SOC process to ensure the research experience is optimized.
Research in Progress Meetings
Research within the ID Division is presented frequently in an informal setting allowing for feedback to help improve the research prior to it being a finished project. Research at any stage is presented by both the fellows and faculty and ranges from early ideas with no data having been obtained to well-conceived projects closer to completion that have residual issues related to design or statistics that the researcher would like assistance with and would benefit from sharing their project with the Division. Often the fellows, during their research year, will take advantage of these meetings as they move forward with their projects as another opportunity for feedback to help shape their research.